Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA internal medicine Jg. 181; H. 10; S. 1276
Hauptverfasser: Dunn, Billy, Stein, Peter, Cavazzoni, Patrizia
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.10.2021
Schlagworte:
Alzheimer Disease - diagnosis
Alzheimer Disease - drug therapy
Amyloid beta-Peptides - antagonists & inhibitors
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - economics
Brain - diagnostic imaging
Brain - pathology
Decision Making
Dose-Response Relationship, Drug
Drug Approval - methods
Humans
Infusions, Intravenous - methods
Magnetic Resonance Imaging - methods
Nootropic Agents - administration & dosage
Nootropic Agents - adverse effects
Nootropic Agents - economics
Plaque, Amyloid - diagnostic imaging
Positron-Emission Tomography - methods
Product Surveillance, Postmarketing
Randomized Controlled Trials as Topic - methods
Treatment Outcome
United States
United States
ISSN:2168-6114, 2168-6114
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2168-6114
2168-6114
DOI:10.1001/jamainternmed.2021.4607